Multicenter study shows high scalp clearance rates for deucravacitinib in psoriasis, suggesting strong therapeutic value.
Deucravacitinib demonstrated clinical effectiveness and a favorable safety profile in real-world practice, including excellent scalp clearance rates, confirming its therapeutic value even in patients with difficult-to-treat areas.
No takes yet. Share an insight, caveat, or question.
Ibba et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: